Clinical trial registry record

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 5, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07630649
Last registry update
August 5, 2026
Status
Recruiting
Phase
Phase 2
Sponsor
Adverum Biotechnologies, Inc.
Enrollment
15
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
15
Population
ALL · 50 Years
Duration
2026-06-02 to 2031-06-01
Intervention
Ixo-vec
Comparator
Not reported
Outcomes measured
Incidence of ocular adverse events (AEs) — Baseline through Week 28; Incidence of ocular serious adverse events (SAEs). — Baseline through Week 28; Incidence of non-ocular serious adverse events (SAEs). — Baseline through Week 28; Mean change from baseline in best corrected visual acuity (BCVA) over time through Week 28. — Baseline through Week 28; Mean change from baseline in central subfield thickness (CST) over time through Week 28. — Baseline through Week 28; Mean number of supplemental aflibercept IVT injections received from Week 4 through Week 28 — Week 4 through Week 28; Percentage of participants who are supplemental aflibercept injection-free through Week 28. — Baseline through Week 28
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON